Brain · part of Brain, memory and mood and Sleep
Does it improve sleep?
Sleep gets claimed constantly and measured rarely. Where a trial used polysomnography rather than a questionnaire, that is worth a great deal more.
187
people in trials
8
studies in people
0
compounds, animal or lab only
16
compounds people report on
2
trials found nothing
Measured in people
A trial that gave people the compound comes first. A study that only watched people, who happened to have more or less of something related, comes after. Both are studies in people and both are here. Only the first kind tested the thing you are asking about, and the watch-only ones are labelled. Within that, the most people come first. That is a fact about the studies, not a judgement about the compound. Counts are never added up across compounds, because the same person can be in more than one trial.
Peptides and blends
4 compounds · 19 people given one of themWhat this archive is for. Trials of the compound come first, ranked by how many people were actually given it. Studies that only observed people are below them and labelled.
- 01SermorelinPeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 139 people given it.8 reported19 people given it1 trial1 found nothing
found nothingThe hormone response faded while the injections carried on. Nineteen adults aged 55 to 71 injected salt water nightly for a month, then a sermorelin-like peptide for four more months. Growth hormone and its main blood marker rose within two weeks, stayed up for three months, then drifted back to where they started even though dosing never stopped. Muscle, insulin response, mood and libido improved in the men and not the women. Bone density and sleep did not change in anyone.
The numbers 19 adults aged 55 to 71 on 4 weeks of placebo then 16 weeks of the Nle27 analogue at 10 micrograms/kg nightly: IGF-1 and IGFBP-3 rose within 2 weeks and returned toward baseline by week 16 while dosing continued. Lean mass, insulin sensitivity, well-being and libido improved in men only; bone mineral density and sleep quality did not change.
Journal of Clinical Endocrinology and Metabolism, 1997· 19 people
What people using it report
- Among those who tolerate it, the reported effects are sleep quality first, then energy, mood and gradual body composition change, and even favourable accounts question whether that is worth the money and the time.
- 02DSIPPeptideLimited. People have taken it in a published study, but fewer than 100 of them. 6 completed trials, 7 people given it.8 reported0 people given it2 trials
Sleep improved slightly, and the researchers said the improvement was not worth much. 16 people with long term sleeplessness were matched into pairs, and nobody knew who got DSIP and who got sugar water. Each had a vein injection before three of five nights in a sleep lab. Those on DSIP fell asleep faster and slept a little more efficiently. Nothing else changed, including how people said they slept. The authors traced part of the gain to a chance shift in the dummy group.
The numbers 16 chronic insomniacs, double-blind matched-pairs parallel groups, 25 nmol/kg intravenously before three of five laboratory nights. Sleep efficiency was higher and latency shorter on DSIP, but the authors judged the effects weak and partly attributable to a change in the placebo group and concluded that short-term treatment is not likely to be of major therapeutic benefit.
Neuropsychobiology, 1992· number of people not given
Withdrawal signs eased, and the study cannot prove the drug did it. 107 hospital patients in Geneva coming off alcohol or opioids got vein injections up to six times a day. Most of those assessed had a clear drop in visible signs: racing heart, tremor, sweating and watering eyes. Within one to three days of stopping, anxiety and severe sleeplessness returned in all but 13. Everybody got the drug, nobody was kept in the dark, and no standard scale was used.
The numbers 107 inpatients in Geneva, 47 with alcohol and 60 with opioid withdrawal, given 25 nmol/kg intravenously up to six times a day for up to six days. Objective withdrawal signs improved markedly in most assessed patients, but anxiety and insomnia relapsed within 24 to 72 hours of stopping in all but 13. Open label, no blinding, no comparison group, no standard scale.
European Neurology, 1984· number of people not given
- 03TirzepatidePeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 9 completed trials, 22,802 people given it.11 reported0 people given it1 trial
It worked for sleep apnea, and the change was big. Adults with obesity and moderate to severe sleep apnea took tirzepatide or a dummy injection for a year, across two trials. Breathing interruptions during sleep dropped by roughly 25 an hour more than on the dummy. That count is the measure doctors use to grade how severe sleep apnea is, so a fall that size moves many people down a grade. These two trials are why the drug carries a sleep apnea licence.
The numbers Two phase 3 trials in moderate-to-severe OSA with obesity: apnea-hypopnea index fell by about 25 events per hour at 52 weeks versus placebo, supporting the Zepbound sleep apnea indication.
New England Journal of Medicine, 2024· number of people not given
- 04GHRP-6PeptideLimited. People have taken it in a published study, but fewer than 100 of them. 5 completed trials, 42 people given it.8 reported0 people given it1 trial1 found nothing
found nothingThis is where the cortisol worry about GHRP-6 comes from, and it is a human measurement. Healthy men were given four small injections across one night, against a dummy on another. Growth hormone roughly tripled, and so did cortisol, with the stress hormone that drives it rising too. Light sleep gained about twenty-five minutes and deep slow-wave sleep did not change. The natural releasing hormone does the opposite to cortisol. That difference is the reason this peptide gets flagged where the other one does not.
The numbers Four 50 microgram intravenous boluses across a night against placebo in normal men. GH 15.4 against 5.5 ng/mL, ACTH 21.0 against 16.6 pg/mL and cortisol 56.0 against 25.2 ng/mL, all p<0.02. Stage 2 sleep rose from 245.4 to 270.1 minutes; slow-wave sleep did not change. The adrenal effect runs opposite to GHRH, which blunts cortisol, and is the human basis for the cortisol concern about this peptide.
Neuroendocrinology, 1995· number of people not given
Other compounds
2 compounds · 168 people given one of themApproved drugs, biologics and hormones that have been measured for this. They are here because leaving them out would misrepresent the evidence, and they are below the peptides because that is not what most people come here to read.
- 01OveporextonSmall moleculeModerate. At least one finished study in people, and at least 100 people who took it. 6 completed trials, 441 people given it.168 people given it2 trials
This is about as strong as evidence for a sleep drug gets. Two trials put people with narcolepsy type 1 on oveporexton pills or dummy pills for three months. Nobody involved knew which. People on the drug stayed awake far longer on a standard staying-awake test, while the dummy group drifted slightly the other way. Daytime sleepiness scores dropped sharply. Sudden episodes of muscle weakness fell by around four fifths. Side effects were much more common on the drug. Takeda paid for both trials.
The numbers First Light (168 participants, 1 mg or 2 mg twice daily or placebo, 3:3:2) and Radiant Light (105 participants, 2 mg twice daily or placebo, 2:1), both 12 weeks, ages 16 to 70. Maintenance of Wakefulness Test sleep latency rose 14.3 to 19.8 minutes with oveporexton against minus 0.4 to minus 0.8 minutes on placebo; Epworth Sleepiness Scale fell 9.7 to 11.8 against 1.5 to 1.7 points; weekly cataplexy fell 79.0 to 88.8 percent against 27.7 to 39.1 percent (all adjusted P below 0.001). Adverse events in 86 to 89 percent against 43 to 54 percent. Funded by Takeda Development Center Americas.
New England Journal of Medicine, 2026· 168 people
The earlier and smaller test pointed the same way. 112 people with narcolepsy type 1 were split by chance across four dose schedules or a dummy, for two months. People on the drug stayed awake much longer on the standard test, while the dummy group slipped slightly. Insomnia hit about half of them, and a third had a sudden or frequent need to pass urine. The authors report no sign of liver damage. Two months is a short look at a lifelong condition. Takeda paid for it.
The numbers Phase 2, 8 weeks, 112 randomised: 90 to four oveporexton regimens (0.5 mg twice daily, 2 mg twice daily, 2 mg then 5 mg, 7 mg once daily) and 22 to placebo. Sleep latency changes of 12.5, 23.5, 25.4 and 15.0 minutes against minus 1.2 on placebo. Insomnia in 48 percent, urinary urgency 33 percent, urinary frequency 32 percent, with no hepatotoxic effects reported. Funded by Takeda.
New England Journal of Medicine, 2025· number of people not given
- 02MK-677Small moleculeLimited. People have taken it in a published study, but fewer than 100 of them. 2 completed trials, 65 people given it.11 reported0 people given it1 trial
MK-677 deepened sleep in young adults. Young and older volunteers each took the drug and a dummy in turn, so every person acted as their own comparison. In the young group the deepest stage of sleep rose by about half, and dreaming sleep by more than a fifth. The figures reported are for the young subjects, not the older ones. The study was small and short, and it measured sleep stages rather than how rested anyone felt.
The numbers Crossover study in young and older adults: high-dose MK-677 increased stage IV sleep by about 50% and REM sleep by more than 20% in young subjects.
Neuroendocrinology, 1997· number of people not given
What people using these actually report
These are people describing their own use. They come from clinic write-ups, complaint records kept by regulators, and public forums, and they are shown as written. They are the best guide on this page to what people actually do, what they expect, and what goes wrong. They cannot show that anything works. Nobody was compared with people on a dummy pill, and people who saw no effect mostly stopped posting. Both things are true at once. The bad reports are kept in for the same reason.
- Among those who tolerate it, the reported effects are sleep quality first, then energy, mood and gradual body composition change, and even favourable accounts question whether that is worth the money and the time.
Sources: Multiple ExcelMale threads including experience, dosing and adverse reaction threads, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- The complaints in that same set are about the same things, not the whole body: trouble sleeping 6, insomnia 5, sleepiness 3, anxiety 3, waking too early 2, low mood 1. People who react badly tend to react in sleep and mood.
Sources: LongeCity 'Telomeres' forum threads on Epitalon and Epithalon; the Age Reversal Forum self-experimentation thread on Epitalon (AEDG); SelfAssay's aggregated community corpus for Epitalon (258 reports, 236 contributors); vendor price tracking at peppers.market (73 vendors, retrieved August 2026). Reddit's r/Peptides is the most cited venue for this compound but was not directly readable when this section was compiled, so nothing here is drawn from it.
- The negative reported most often is sleep. Taking it later in the day is repeatedly described as producing enough stimulation to prevent sleep or to cause waking in the early hours, and insomnia appearing after several consecutive days shows up as a distinct pattern.
Sources: The NMN personal experience threads, the under the tongue thread, supplier and purity threads, and the NAD+ subforum generally on LongeCity, found by site-restricted search, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- Sleep reports contradict each other flatly. Insomnia on it is common, and so is the report that a higher dose makes people sleepy, and both come from experienced users.
Sources: MESO-Rx threads on thinksteroids.com about HGH dosing, what people feel on it, side effects, generic product identification and whether it is worth the cost, plus ExcelMale threads on carpal tunnel symptoms, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- The negatives that recur are estrogen related: water retention, acne and breast tenderness, with anxiety, insomnia or raised blood pressure after injections described by a smaller group.
Sources: Long-running HCG threads on ExcelMale covering use on testosterone replacement and on its own, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- The sharpest negative is anxiety. Rising anxiety, irritability, insomnia and in some accounts a first panic attack are described after starting the methylated form, and people who report this generally describe it as clearly tied to the supplement and resolving when they stop.
Sources: Supplements, Brain Health and Mental Health threads on LongeCity on methylcobalamin reactions, anxiety and sedation, plus ExcelMale dosing discussion, found by site-restricted search, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- Mouth sores and rashes are the most consistently described problem, and people describe them settling when they pause or lower the dose. Raised blood glucose is discussed as an expected consequence rather than a surprise, insomnia is described after the first doses, and worry about lowered white blood cells and infection risk recurs without an answer.
Sources: Rapamycin experience and dosing threads on LongeCity, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- Side effects described include insomnia, nipple sensitivity and worry about gynecomastia, temperature dysregulation with alternating chills and short hot flashes, low mood, anxiety and skin sensitivity. In restart contexts these are described as lasting two to three months before easing.
Sources: Enclomiphene dosing, restart and experience threads on ExcelMale, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- Testicular shrinkage is described as common enough to plan for, and the usual answer described is adding hCG. Acne, oily skin, hair loss and worsened sleep apnoea come up regularly.
Sources: Long-running testosterone protocol, side effect and monitoring threads on ExcelMale, found by site-restricted search and read in September 2026. This material is closer to accumulated board guidance than to individual experience reports, and is described as such above. Nothing is attributed to any specific post and no post is reproduced.
- Used without testosterone, the body's own testosterone is described as shutting down fast and completely. Testosterone and estrogen both fall sharply in the logs, and symptoms people put down to low estrogen, such as joint cracking, are described after less than a week at the higher end of the doses above. Insomnia, loss of sexual function and elevated liver enzymes appear in the same accounts, and posters note the liver findings sit awkwardly with the claim that this compound is handled differently from other orals.
Sources: Oxandrolone threads on ExcelMale, including self-logs with bloodwork, found by site-restricted search and through the site's tag index, read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- Fatigue and grogginess are reported more than anything else, and specifically at the higher end. The workarounds people describe are moving the dose to the evening or lowering it, and the reports conflict directly: some describe morning dosing causing grogginess, others describe evening dosing causing insomnia.
Sources: DHEA safety, dosing and side effect threads on ExcelMale, plus supplement threads on LongeCity, found by site-restricted search and read in September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- Side effect reports are thin beyond insomnia and overstimulation, and posters note that most of the safety framing in circulation traces back to the manufacturer rather than to independent work. Availability and doubts about what is actually in the capsule come up often.
Sources: Brain Health and Nootropic Stacks threads on LongeCity and misc threads on Bluelight, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- Hand tremor bad enough to interfere with writing, insomnia, heavy sweating, headache, breathlessness during training, raised blood pressure and a sense of dull thinking all appear repeatedly.
Sources: Clenbuterol threads on Bluelight, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- Sleep is the most consistent negative. Taking it in the afternoon or evening is repeatedly described as producing racing thoughts and physical restlessness that prevent sleep, and insomnia with early waking after several consecutive days appears as a distinct pattern.
Sources: Supplements and Brain Health threads on LongeCity, including the multi-page verdict thread, the experience threads and threads on arrhythmia and insomnia, found by site-restricted search, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- Negatives described include carpal tunnel type symptoms in the hands appearing around week five, daytime sleepiness, early insomnia, and appetite increase attributed to the paired ghrelin mimetic. The strict food timing is repeatedly described as the hardest part to sustain.
Sources: Growth hormone peptide threads on ExcelMale, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
- Constipation is the side effect described in most detail, by people who report it persisting across many brands, amounts and timings and not responding to fibre, water or magnesium, while others at the same amounts report nothing at all. Digestive upset at higher amounts, hypercalcaemia at very high blood levels, and questions about insomnia after injections also appear.
Sources: Vitamin D threads on ExcelMale covering high dose use, reported side effects and disagreement over target blood levels, found by site-restricted search and read directly, September 2026. Nothing above is attributed to any specific post and no post is reproduced.
Why the trial record looks like this
A missing trial usually means nobody would pay for it. Nobody spends hundreds of millions of dollars on a molecule they cannot own. So the compounds with the thinnest record in people are often the oldest and easiest to get, not the weakest. Taking Oveporexton as the example, because it states the problem most clearly:
The record is short because the path was fast. It is a rare disease. The drug goes straight at the known cause. And the maker had already taken an earlier drug of this type (TAK-994) far enough to find liver damage and stop it. Everything published on oveporexton is paid for by Takeda. That includes the earlier study, the two big studies, and the paper that set the bar for a meaningful attention change. That is normal for a new drug, and worth saying. The approval came less than a month before the big studies were published. So for a few weeks, the only approval record was the company's own announcement. The FDA's drug database now carries the application (NDA 220860, approved 5 August 2026) and the label, and this page is built from those.
The honest tension here is benefit against side effects. The stay-awake effect is large for this field. So are the side effects. Most people get trouble sleeping at night at the start, and most need to pee more often. The label says 17 percent of the sleep trouble was still there at week 12, and that is the number to watch. Will people stay on it for years? What does a small rise in a muscle enzyme mean over that time? No current study answers either. The label also lists its controlled drug schedule as pending. A drug that makes you awake on demand gets checked for abuse.
A compound shows up here only when a study on its own page names this goal and reports a result for it. Just naming it is not enough. Work in people, in animals and in the lab is counted separately and never mixed. People counts come from the study lines, and when in doubt they count low. Nothing here is advice. Nothing here tells you to take or to avoid anything.